< BACK European Researchers' Night Sep 30, 2024 Engaging Communities through Science Bárbara Ramalho, Hugo Escobar, and Marta Vicente from FMH/IST-ULisboa presented the iPROLEPSIS Games and the iPROLEPSIS project at the European Researchers' Night in Oeiras, Portugal. This event, part of the "Science for Everyone (SCIEVER) – Inclusion and Sustainability" initiative, aimed to engage the public with scientific advancements. Researchers from various fields participated, sharing their work through interactive presentations, live demonstrations, and diverse activities, fostering a stronger connection between science and the community. The event unerlined the importance of making scientific research accessible to all. 1/4 PREVIOUS NEXT

iProlepsis project for psoriatic arthritis uses multi-source data analysis for guiding to a novel personalised digital care ecosystem and maximizes the impact. iPROLEPSIS project vision and impact maximisation Health-to-PsA transition through multi-source data analysis guiding to a novel personalised digital care ecosystem and impact maximisation through openness, visibility, networking and reuse of outcomes. Project vision Data analysis, iPROLEPSIS project goals, IoT technologies and mobile application. About Psoriatic Arthritis Psoriatic Arthritis (PsA) is a chronic, inflammatory disease, affecting the peripheral and axial skeleton, with a severe impact on patients’ quality-of-life. It is estimated that 1-2% of the general population has PsA, i.e., 5 to 10 million people in EU are affected . PsA is associated with psoriasis (PsO) and up to 30% of people living with PsO, i.e., at least 100 million people worldwide (WHO), are expected to develop PsA. The goal The goal of iPROLEPSIS is to propose a novel ecosystem that involves Real Worl Data (RWD) collection mechanisms and a powerful decision support system to provide new knowledge for the key actionable factors that affect the health-to-PsA transition, adopting a multiscale/ multifactorial approach, so, with the use of xAI-based models, to offer an efficient, effective, and clinically validated personalised digital care ecosystem for PsA patients. Technologies IoT sensing technologies and a mobile application will be at the heart of the RWD collection procedure, while retrospective and prospective multi-source data will be collected from the clinical partners’ databases, combined with open access ones. Through the analysis and visualisation of these data using AI predictive models and an intuitive visual analytics tool, respectively, the iPROLEPSIS will be able to propose personalized treatments (i.e., diet, physical activity, stress/fatigue/pain management), assisting doctors, caregivers, and hospitals towards the optimal management of PsA. Finally, through xAI techniques, iPROLEPSIS aims to facilitate hospitals and policy makers in gaining new insights towards better clinical practices, thus shaping future PsA treatment policies. Impact maximisation To ensure the successful implementation of the pathways towards impact in long-term, the project consortium aims at making iPROLEPSIS a reference for the fight against PsA by: 01 Creating an active iPROLEPSIS community of stakeholders. 02 Informing key stakeholders about results and their clinical innovation potential. 03 Making the outputs widely available for research and business purposes in the long term. 04 Increasing people with/at risk of PsA engagement for addressing their issues and concerns in order to increase their awareness and to build trust into new technology. 05 Reaching similar/relevant R&I projects for promoting networking and joint activities. 06 Establishing a forum/community for HCPs and authorities to develop new guidelines and standards. 07 Identifying exploitation mechanisms and activities, assessing the commercialization and applicability of the concepts and ideas. PROJECT OBJECTIVES

< BACK iPROLEPSIS Newsletter No. 6 Oct 9, 2024 Latest News from iPROLEPSIS Welcome to the 6th edition of the iPROLEPSIS newsletter. In this edition, we share the latest updates and progress from our project, including new developments, recent publications, and reflections on key events. iPROLEPSIS project newsletter_October 2024_ Issue No. 6 .pdf Download PDF • 4.41MB 1/1 PREVIOUS NEXT

Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search Quizzes What is psoriatic arthritis? Take a Quiz What are the symptoms of psoriatic arthritis? Take a Quiz How is psoriatic arthritis treated? Drug treatments Take a Quiz How is psoriatic arthritis treated? Self-care and lifestyle Take a Quiz How will psoriatic arthritis affect me? Sleep and Fatigue Take a Quiz How will psoriatic arthritis affect me? Relationships and Family Planning Take a Quiz What causes psoriatic arthritis? Take a Quiz How is psoriatic arthritis diagnosed? Take a Quiz How is psoriatic arthritis treated? Non-pharmacological treatments Take a Quiz How will psoriatic arthritis affect me? Work Take a Quiz How will psoriatic arthritis affect me? Emotional wellbeing Take a Quiz

< BACK iPROLEPSIS at Healthcare & Medical Equipment Korea 2026 Apr 1, 2026 Presenting iPROLEPSIS at Korea’s leading medical technology exhibition Healthcare & Medical Equipment Korea 2026 (KIMES 2026) took place in Seoul, South Korea, from 19 to 22 March 2026. As Korea’s largest specialised exhibition for medical devices and hospital facilities, the event showcased developments in areas such as smart healthcare, AI, robotic medicine, rehabilitation, and medical information systems. iPROLEPSIS was represented at the event by project partner PLUX. The project was presented to an international audience, helping to raise its visibility in the healthcare technology field. The event also provided valuable networking opportunities and supported exchange around biosignal wearables and related digital health solutions. _09A1849.jpg 1.jpg _09A1849.jpg 1/2 PREVIOUS NEXT

< BACK iPROLEPSIS presented at the European OHDSI Symposium 2026 Apr 23, 2026 A poster presented in Rotterdam highlighted cross-country harmonization of psoriatic arthritis cohorts into the OMOP Common Data Model At the European OHDSI Symposium 2026 in Rotterdam, project partner AINIGMA presented a poster entitled Cross-Country Harmonization of Psoriatic Arthritis Cohorts: A Real-World Data Study in the context of the iPROLEPSIS project. Psoriatic arthritis affects 1–2% of the population and shows substantial heterogeneity in symptoms, progression, and treatment response. Real-world evidence is essential to understand long-term outcomes, sex differences, and disease trajectories that are difficult to capture in clinical trials. To identify key inflammation drivers, the team harmonised two national psoriatic arthritis cohorts – the Portuguese Reuma.pt registry and the Dutch DEPAR cohort – into the OMOP Common Data Model (OMOP CDM). This enabled standardised cross-country and sex-stratified analyses. The poster also presented data quality results for this harmonisation work, showing a 95% overall pass rate, including 99% for plausibility, 88% for conformance, and 90% for completeness. As highlighted in the conclusion of the poster, this work shows the value of harmonising data from different national psoriatic arthritis registries into the OMOP CDM to make standardised real-world analyses across European healthcare systems possible. It also opens up new possibilities for advanced analytics, such as federated studies and AI-driven prediction models, beyond this proof-of-concept analysis, advancing iPROLEPSIS’s goal of personalised, data-driven care. Poster_Final_Cross-Country Harmonization of Psoriatic Arthritis Cohorts A real-world data .pdf Download PDF • 1.66MB Media.jpg Media (1).jpg Media (2).jpg Media.jpg 1/3 PREVIOUS NEXT

< BACK iPROLEPSIS Plenary meeting Jun 23, 2023 iPROLEPSIS Consortium Partners Meet in Lisbon to Plan Next Steps The iPROLEPSIS consortium partners gathered in Lisbon, Portugal on June 20-21 for the 2nd Plenary meeting to review the progress and achievements of the project's work packages and plan the next steps. Over the course of two days, the consortium partners engaged in three productive workshops, each focusing on key aspects of the iPROLEPSIS project: Data Collection and Digital Biomarkers: The first workshop delved into the vital task of data collection and the development of digital biomarkers. Attendees discussed the identification of sensor and user data to be collected, including accelerometer/gyroscope data. Additionally, they explored algorithms for identifying inflammation drivers and defined user profiles to enhance personalized healthcare. System Architecture and Cloud Back-end: The second workshop centered around system architecture. The consortium partners discussed the key components of the system, including the orchestrator, and addressed critical aspects such as data management infrastructure and monitoring of app performance issues. miPROLEPSIS App and Serious Games: The third workshop involved a dynamic co-creation session, bringing together clinicians, patients, researchers, and developers. Focusing on the miPROLEPSIS app and serious games, participants explored various areas such as system architecture, key components, data management infrastructure, and app performance monitoring. The adoption of the "Crazy 8s" technique allowed for the rapid generation of a diverse range of ideas. During the third workshop patient representatives joined the session. Their valuable input and perspectives are crucial for understanding the specific needs and requirements of those who will benefit from our iPROLEPSIS project. By actively involving patient representatives, we can ensure that our solutions are truly patient-centric and tailored to their experiences and challenges. The iPROLEPSIS consortium is excited about the progress made during this meeting and is now equipped with a comprehensive plan for the next steps of the project. 3-1.jpg 3-1.jpg 1/1 PREVIOUS NEXT

< BACK Designing Exergames for Psoriatic Arthritis: The Spy and Zen Forest Paradigms Feb 4, 2026 New iPROLEPSIS publication presents the co-design of exergames to support physical activity and rehabilitation in psoriatic arthritis A new publication from the iPROLEPSIS project has been published in the proceedings of the 2025 IEEE International Conference on E-health Networking, Application & Services (HealthCom) . Psoriatic arthritis (PsA) is a rheumatic disease affecting the skin and joints and is commonly associated with stiffness, impaired mobility, and chronic pain. In addition to biological treatments, physiotherapy and exercise are often recommended to improve range of motion and physical function. However, low adherence, high costs, and limited engagement frequently reduce the effectiveness of these interventions. The paper presents the design of two exergames – The Spy and Zen Forest – developed as accessible digital tools to complement traditional rehabilitation approaches. Exergames embed therapeutic movements into game mechanics, supporting motivation and consistency in physical activity. Both games were co-designed with 29 experts , including patients with psoriatic arthritis, clinicians, researchers, and technical stakeholders, to ensure alignment with clinical goals, patient needs, and safe physical engagement. In The Spy , players complete physically engaging missions designed to stimulate dynamic body movement and support coordination, mobility, balance, strength, and flexibility. Zen Forest focuses on slow, calm stretching routines inspired by Pilates and Yoga, promoting flexibility, relaxation, and body awareness. Together, the exergames aim to support personalised activity routines and enable clinicians to monitor progress and recommend tailored interventions. Read the full publication: https://zenodo.org/records/18468928 iPROLEPSIS_Zen and Spy.png iPROLEPSIS_Zen and Spy.png 1/1 PREVIOUS NEXT

Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search RSS News Feed Psoriatic Arthritis articles within Nature Reviews Rheumatology Journal of Psoriasis and Psoriatic Arthritis National Psoriasis Foundation

< BACK iPROLEPSIS Games Presented at the Pitch Competition during PhD Open Days Nov 7, 2024 Showcasing iPROLEPSIS Games at the PhD Open Days Pitch Competition On November 5th, Bárbara Ramalho from FMH/IST-ULisboa had the opportunity to present the iPROLEPSIS Games at the Pitch Competition during the PhD Open Days event at the Técnico Innovation Center . In her pitch, Bárbara highlighted the role of serious games in the iPROLEPSIS project, which aims to improve the care and management of psoriatic arthritis (PsA) through a personalised, game-based digital ecosystem. The PhD Open Days gave over a thousand students the chance to connect, network, and showcase their research to the academic community, industry professionals, and alumni. The Pitch Competition was a great opportunity for researchers to present their work and meet potential collaborators. 1/5 PREVIOUS NEXT

< BACK Trustworthy AI in Digital Health: The iPROLEPSIS Approach Mar 28, 2025 iPROLEPSIS at Health Data Summit 2025 At Health Data Summit 2025 , organised by The European Institute for Innovation Through Health Data on March 18–19 in Brussels , Vasileios Charisis, PhD , from the Signal Processing & Biomedical Technology Unit - AUTH , presented iPROLEPSIS during the session “Trustworthy AI in Digital Health: From Guidelines to Practice”. The presentation outlined the methodology used in iPROLEPSIS to develop a trustworthy AI (TAI) framework tailored to the project’s specific needs. A case study on the Lifestyle Recommendation Engine demonstrated how it aligns with TAI principles and recommendations . The session also featured other Horizon Europe projects , including AI-PROGNOSIS, TRUSTroke, and STRATIFYHF , which presented their approaches to developing trustworthy digital health solutions . By bringing together different initiatives, the session highlighted the importance of trustworthy AI in healthcare , ensuring transparency, reliability, and ethical considerations in digital health innovations . 1/3 PREVIOUS NEXT

Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Handbook Learning hub Key Facts Handbook News Feed Quizzes Search Handbook 1 Psoriatic Arthritis Handbook Understanding Psoriatic Arthritis h1.1 What is psoriatic arthritis? Psoriatic arthritis is a type of arthritis linked with psoriasis, a chronic skin and nail disease. Psoriasis causes red, scaly rashes and thick, pitted fingernails. Psoriatic arthritis is characterized by joint swelling (inflammation), pain and stiffness and can affect any peripheral joint such as fingers, toes, knees and/or spine. It also affects the insertion of tendons or ligaments in bones (enthesitis). Between 20-40% of people with the skin condition psoriasis will develop psoriatic arthritis (1, 2). Symptoms affecting their joints tend to develop 5 to 10 years after psoriasis is diagnosed but it can occur at any time (3). Currently, it is not clear why some people with psoriasis develop psoriatic arthritis while others do not. The arthritis of psoriatic arthritis comes in 3 forms: oligoarticular arthritis that affects 4 or less peripheral joints (e.g., joints in the fingers, toes, knees); polyarticular arthritis that involves 5 or more peripheral joints on both sides of the body; and axial arthritis that affects the joints of the spine including the sacroiliac joint (where the spine connects to the pelvis). Some people may develop psoriasis after or at the same time as symptoms of psoriatic arthritis present themselves (4). In rare cases, people may have psoriatic arthritis and never have any noticeable symptoms of psoriasis. Psoriatic arthritis and psoriasis are chronic inflammatory conditions that are caused by a fault in the immune system. Our immune system protects us from infection and illness. See related Key Facts section What causes psoriatic arthritis? While psoriatic arthritis can occur at any age, most people present their first signs and symptoms at 30-50 years. Psoriatic arthritis is most likely to be diagnosed within the first ten years of the psoriasis diagnosis (3). Psoriatic arthritis affects both sexes equally. However, the manifestations in terms of severity and impact of the disease differ between sexes. Men are more likely to have involvement of the bones in the spine (axial arthritis) and radiographic damage in the spine and peripheral joints (e.g., fingers, knees and toes), whereas women are more likely to experience impaired quality of life and severe limitations in function (5). Researchers are not sure why some people develop psoriatic arthritis. It is thought that certain genes inherited from parents and grandparents can make a person more likely to develop psoriatic arthritis (6–8). h1.2 In people with a higher genetic predisposition to develop psoriatic arthritis, the condition can be triggered by environmental factors, such as: an infection (9); an accident or injury (10, 11); being overweight (12); smoking (13, 14). Psoriasis and psoriatic arthritis are not contagious. You cannot catch psoriasis or psoriatic arthritis from other people. See related Key Facts section What are the symptoms of psoriatic arthritis? Psoriatic arthritis symptoms usually develop slowly, that is, many people are unaware that they are developing psoriatic arthritis (Figure 1). Although symptoms can develop suddenly in rarer cases. Some of the main symptoms include (15): pain in one or more joints; swelling in one or more joints; stiffness in one or more joints that lasts for 30 minutes or longer. These symptoms are caused by inflammation and can affect any joint in the body. See Figure 2 for the most commonly affected joints. See related Key Facts section h1.3 Psoriatic arthritis can cause pain and swelling in the entheses, that is, places in the body where tendons and ligaments connect to the bones (15). When the entheses become inflamed it is known as enthesitis. Enthesitis pain can spread along a wider area than joint pain. It frequently occurs at the back of the heel or on the bottom of the foot, which can make standing or walking difficult. Affected areas feel tender to touch even when just a small amount of pressure is applied. The knees, hips, elbows and chest can also be affected by enthesitis. Many people with psoriatic arthritis have swollen fingers or toes, a condition that is known as dactylitis (15) (Figure 1). It most commonly affects one or two fingers or toes at a time. Psoriatic arthritis can also cause small round dents in fingernails and/or toenails, a condition known as pitting. The nails can change colour, become thicker, or even lift away from your finger (15). People living with psoriatic arthritis may feel very tired (fatigued) and some may have a low-grade fever. Fatigue does not get better with rest. Psoriatic arthritis symptoms may come and go. A period of increased inflammation and worsening of other symptoms is called a flare. A flare can last for days or months See related Key Facts section h1.5 How is psoriatic arthritis diagnosed? A timely and accurate diagnosis is an important step for optimising care and improve long-term health outcomes (16). If you have been diagnosed with psoriasis in the past, and symptoms of arthritis (e.g., painful or swollen joints) have started more recently, you may have developed psoriatic arthritis. However, the symptoms of psoriatic arthritis can look like other health conditions. Make sure to see your healthcare provider for a diagnosis. The doctor you see first may depend on whether you have previously been diagnosed with psoriasis. If you develop symptoms of arthritis your primary care or skin doctor should refer you to a rheumatologist – a doctor who specialises in joint conditions – for an assessment. Tell your doctor if you have a history of psoriasis and/or psoriatic arthritis in your family. CURRENTLY, NO SINGLE TEST CAN CONFIRM PSORIATIC ARTHRITIS (15). A diagnosis will be made based on your medical history, symptoms, and a physical examination by your doctor. Your doctor may order X-rays or other types of imaging, such as ultrasound scans and magnetic resonance imaging (MRI), to look for changes to your bones and joints. Imaging studies will help your doctor determine the type and pattern of joint involvement, which can also help them distinguish between arthritis types. Blood tests, such as erythrocyte sedimentation rate and C-reactive protein, can help to identify inflammation. Your doctor may also order tests for rheumatoid factor and the anti-CCP antibody to rule out rheumatoid arthritis and HLA-B types to look for your genetic predisposition to spondylarthritis. See related Key Facts section h1.4 See related Key Facts Previous page Next page